Summary
A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder. Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors. Instillation was repeated twice during the first week, then weely during the first month and afterwards monthly for 1 year. The tolerance was evaluated in these 110 patients, and 29 patients presented with local side-effects. In 24 of these patients chemical cystitis was severe enough for them to drop out of the study. No systemic side-effects were observed.
Recurrence was studied in 82 evaluable patients after 1 year of follow-up and in 72 patients followed for 2–3 years (mean 32 months). Of the 82 patients studied after 1 year, 23 had primary and 59 recurrent disease. Of the 82 evaluable patients, 50 did not show any recurrence after 1 year (61%), while 32 presented with one or more recurrence (39%). Of these recurrences, 27 were T1 tumors while five progressed to more highly invasive lesions. In patients that were free of recurrence during the first year, 80% remained tumor-free during the 2- to 3-year follow-up period. Of the patients developing one or more recurrences during the first year, only 50% presented with further recurrence once the instillations were stopped. The beneficial effect of Adrimacin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.
Similar content being viewed by others
References
Banks MD, Pontes JE, Izbicki RM, Pierce JM Jr (1977) Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. J Urol 118: 757
Edsmyr F, Berlin T, Boman J, Duchek M, Esposti PL, Gustafson H, Wilktrom H (1978) Intravesical therapy with Adriamycin in patients with superficial bladder tumors. In: WHO Collaborating Centre Conference on Diagnostics and Treatment of Superficial Urinary Bladder Tumors. pp 45–53
Greene LF, Hanash KA, Farrow GM (1973) Bening papilloma or papillary carcinoma of the bladder? J Urol 110: 205
Horn Y, Eidelman A, Walach N, Ilian M (1981) Intravesical chemotherapy in a controlled trial with thio-TEPA versus doxorubicin hydrochloride. J Urol 125: 652
Jacobi GH, Kurth KH (1980) Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumour penetration. J Urol 124: 34
Jakse G, Hofstadter F, Marberger H (1981) Intracavitary doxorubicin hydrochloride therapy for carcinoma in-situ of the bladder. J Urol 125: 185
Jones HC, Swinney J (1961) Thio-TEPA in the treatment of tumors of the bladder. Lancet II: 615
Lerman RI, Hutter RV, Whitmore WF Jr (1970) Papilloma of the urinary bladder. Cancer 25: 333
Niijima T (1978) Intravesical therapy with Adriamycin and new trends in the diagnostics and therapy of superficial urinary bladder tumours. In: WHO Collaborating Centre Conference on Diagnostics and Treatment of Superficial Urinary Bladder Tumors. pp 37–44
Pyrah LN, Raper FP, Thomas GM (1964) Report of a follow-up of papillary tumours of the bladder. Br J Urol 36: 14
Schulman C, Robinson M, Denis L, Smith P, Viggiano G, De Pauw M, Delasio O, Sylvester R (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an E.O.R.T.C. randomized trial comparing thio-TEPA, an epipodophyllotoxin (VM26) and TUR alone. Eur J Urol 8: 207
Soloway MS (1980) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123: 461
Williams JL, Hammonds JC, Saunders N (1977) T1 bladder tumors. Br J Urol 49: 663
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schulman, C.C., Denis, L.J., Oosterlinck, W. et al. Early adjuvant Adriamycin in superficial bladder carcinoma. Cancer Chemother. Pharmacol. 11 (Suppl 1), S32–S34 (1983). https://doi.org/10.1007/BF00256714
Issue Date:
DOI: https://doi.org/10.1007/BF00256714